{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T11:44:28Z","timestamp":1794483868261,"version":"4.9.1"},"reference-count":193,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T00:00:00Z","timestamp":1566432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T00:00:00Z","timestamp":1566432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1038\/s41575-019-0186-y","type":"journal-article","created":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T07:03:20Z","timestamp":1566457400000},"page":"589-604","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3674,"title":["A global view of hepatocellular carcinoma: trends, risk, prevention and management"],"prefix":"10.1038","volume":"16","author":[{"given":"Ju Dong","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Hainaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3151-009X","authenticated-orcid":false,"given":"Gregory J.","family":"Gores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Amadou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelie","family":"Plymoth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7885-8574","authenticated-orcid":false,"given":"Lewis R.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,22]]},"reference":[{"key":"186_CR1","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","volume":"3","author":"Global Burden of Disease Cancer, C.","year":"2017","unstructured":"Global Burden of Disease Cancer, C. et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 3, 524\u2013548 (2017).","journal-title":"JAMA Oncol."},{"key":"186_CR2","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1053\/j.gastro.2007.04.061","volume":"132","author":"HB El-Serag","year":"2007","unstructured":"El-Serag, H. B. & Rudolph, K. L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132, 2557\u20132576 (2007).","journal-title":"Gastroenterology"},{"key":"186_CR3","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2011.12.061","volume":"142","author":"HB El-Serag","year":"2012","unstructured":"El-Serag, H. B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142, 1264\u20131273 e1261 (2012).","journal-title":"Gastroenterology"},{"key":"186_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00261-017-1209-1","volume":"43","author":"A Tang","year":"2018","unstructured":"Tang, A., Hallouch, O., Chernyak, V., Kamaya, A. & Sirlin, C. B. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom. Radiol. (NY) 43, 13\u201325 (2018).","journal-title":"Abdom. Radiol. (NY)"},{"key":"186_CR5","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.2008.20.7753","volume":"27","author":"SF Altekruse","year":"2009","unstructured":"Altekruse, S. F., McGlynn, K. A. & Reichman, M. E. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J. Clin. Oncol. 27, 1485\u20131491 (2009).","journal-title":"J. Clin. Oncol."},{"key":"186_CR6","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nrgastro.2013.107","volume":"10","author":"B Hajarizadeh","year":"2013","unstructured":"Hajarizadeh, B., Grebely, J. & Dore, G. J. Epidemiology and natural history of HCV infection. Nat. Rev. Gastroenterol. Hepatol. 10, 553\u2013562 (2013).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"186_CR7","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1111\/liv.12818","volume":"35","author":"JW Park","year":"2015","unstructured":"Park, J. W. et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the bridge study. Liver Int. 35, 2155\u20132166 (2015).","journal-title":"Liver Int."},{"key":"186_CR8","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1038\/ajg.2015.289","volume":"110","author":"JD Yang","year":"2015","unstructured":"Yang, J. D. et al. Hepatocellular carcinoma occurs at an earlier age in Africans, particularly in association with chronic hepatitis B. Am. J. Gastroenterol. 110, 1629\u20131631 (2015).","journal-title":"Am. J. Gastroenterol."},{"key":"186_CR9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/cncr.30246","volume":"123","author":"JD Yang","year":"2017","unstructured":"Yang, J. D., Altekruse, S. F., Nguyen, M. H., Gores, G. J. & Roberts, L. R. Impact of country of birth on age at the time of diagnosis of hepatocellular carcinoma in the United States. Cancer 123, 81\u201389 (2017).","journal-title":"Cancer"},{"key":"186_CR10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S2468-1253(16)30161-3","volume":"2","author":"JD Yang","year":"2017","unstructured":"Yang, J. D. et al. Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. Lancet Gastroenterol. Hepatol. 2, 103\u2013111 (2017).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"186_CR11","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1159\/000484619","volume":"7","author":"M Kudo","year":"2018","unstructured":"Kudo, M. Management of hepatocellular carcinoma in Japan as a world-leading model. Liver Cancer 7, 134\u2013147 (2018).","journal-title":"Liver Cancer"},{"key":"186_CR12","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/nrgastro.2010.100","volume":"7","author":"JD Yang","year":"2010","unstructured":"Yang, J. D. & Roberts, L. R. Hepatocellular carcinoma: a global view. Nat. Rev. Gastroenterol. Hepatol. 7, 448\u2013458 (2010).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"186_CR13","unstructured":"World Health Organization. Global health sector strategy on viral hepatitis 2016\u20132021. WHO https:\/\/www.who.int\/hepatitis\/strategy2016-2021\/ghss-hep\/en\/ (2016)."},{"key":"186_CR14","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/S0140-6736(18)32277-3","volume":"393","author":"A Heffernan","year":"2019","unstructured":"Heffernan, A., Cooke, G. S., Nayagam, S., Thursz, M. & Hallett, T. B. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. Lancet 393, 1319\u20131329 (2019).","journal-title":"Lancet"},{"key":"186_CR15","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1038\/ajg.2016.330","volume":"111","author":"JD Yang","year":"2016","unstructured":"Yang, J. D. et al. Diabetes mellitus heightens the risk of hepatocellular carcinoma except in patients with hepatitis c cirrhosis. Am. J. Gastroenterol. 111, 1573\u20131580 (2016).","journal-title":"Am. J. Gastroenterol."},{"key":"186_CR16","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.jhep.2016.09.013","volume":"66","author":"M Chayanupatkul","year":"2017","unstructured":"Chayanupatkul, M. et al. Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection. J. Hepatol. 66, 355\u2013362 (2017).","journal-title":"J. Hepatol."},{"key":"186_CR17","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/hep.28785","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi, Z. M. et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 64, 1577\u20131586 (2016).","journal-title":"Hepatology"},{"key":"186_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73\u201384 (2016).","journal-title":"Hepatology"},{"key":"186_CR19","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1002\/hep.28123","volume":"62","author":"ZM Younossi","year":"2015","unstructured":"Younossi, Z. M. et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 62, 1723\u20131730 (2015).","journal-title":"Hepatology"},{"key":"186_CR20","first-page":"742","volume-title":"J. Clin. Gastroenterol.","author":"JD Yang","year":"2017","unstructured":"Yang, J. D. et al. Recent trends in the epidemiology of hepatocellular carcinoma in Olmsted county, Minnesota: a US population-based study. J. Clin. Gastroenterol. 51, 742\u2013748 (2017)."},{"key":"186_CR21","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1038\/ajg.2013.160","volume":"108","author":"TM Welzel","year":"2013","unstructured":"Welzel, T. M. et al. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am. J. Gastroenterol. 108, 1314\u20131321 (2013).","journal-title":"Am. J. Gastroenterol."},{"key":"186_CR22","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.cgh.2015.07.019","volume":"14","author":"S Mittal","year":"2016","unstructured":"Mittal, S. et al. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 14, 124\u2013131 e121 (2016).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"186_CR23","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.cgh.2005.12.007","volume":"4","author":"HB El-Serag","year":"2006","unstructured":"El-Serag, H. B., Hampel, H. & Javadi, F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin. Gastroenterol. Hepatol. 4, 369\u2013380 (2006).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"186_CR24","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1002\/hep4.1182","volume":"2","author":"SF Huang","year":"2018","unstructured":"Huang, S. F. et al. Metabolic risk factors are associated with non-hepatitis B non-hepatitis C hepatocellular carcinoma in Taiwan, an endemic area of chronic hepatitis B. Hepatol. Commun. 2, 747\u2013759 (2018).","journal-title":"Hepatol. Commun."},{"key":"186_CR25","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S0140-6736(00)04046-0","volume":"357","author":"F Balkwill","year":"2001","unstructured":"Balkwill, F. & Mantovani, A. Inflammation and cancer: back to Virchow? Lancet 357, 539\u2013545 (2001).","journal-title":"Lancet"},{"key":"186_CR26","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature01137","volume":"420","author":"J Hirosumi","year":"2002","unstructured":"Hirosumi, J. et al. A central role for JNK in obesity and insulin resistance. Nature 420, 333\u2013336 (2002).","journal-title":"Nature"},{"key":"186_CR27","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1172\/JCI37156","volume":"118","author":"L Hui","year":"2008","unstructured":"Hui, L., Zatloukal, K., Scheuch, H., Stepniak, E. & Wagner, E. F. Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J. Clin. Invest. 118, 3943\u20133953 (2008).","journal-title":"J. Clin. Invest."},{"key":"186_CR28","unstructured":"Norat, T., Aune, D., Navarro, D. & Abar, L. Diet, nutrition, physical activity and liver cancer. World Cancer Research Fund International. https:\/\/www.wcrf.org\/sites\/default\/files\/Liver-Cancer-2015-Report.pdf (2015)."},{"key":"186_CR29","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1111\/apt.13961","volume":"45","author":"J West","year":"2017","unstructured":"West, J., Card, T. R., Aithal, G. P. & Fleming, K. M. Risk of hepatocellular carcinoma among individuals with different aetiologies of cirrhosis: a population-based cohort study. Aliment. Pharmacol. Ther. 45, 983\u2013990 (2017).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"186_CR30","doi-asserted-by":"publisher","first-page":"841","DOI":"10.7326\/0003-4819-156-12-201206190-00004","volume":"156","author":"P Jepsen","year":"2012","unstructured":"Jepsen, P., Ott, P., Andersen, P. K., Sorensen, H. T. & Vilstrup, H. Risk for hepatocellular carcinoma in patients with alcoholic cirrhosis: a Danish nationwide cohort study. Ann. Intern. Med. 156, 841\u2013847, W295 (2012).","journal-title":"Ann. Intern. Med."},{"key":"186_CR31","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.cgh.2012.09.007","volume":"11","author":"A Mancebo","year":"2013","unstructured":"Mancebo, A. et al. Annual incidence of hepatocellular carcinoma among patients with alcoholic cirrhosis and identification of risk groups. Clin. Gastroenterol. Hepatol. 11, 95\u2013101 (2013).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"186_CR32","unstructured":"Wild, C. P., Miller, J. D. & Groopman, J. D. Mycotoxin Control in Low- and Middle-Income Countries Vol. 9 (IARC, 2015)."},{"key":"186_CR33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.canlet.2009.02.057","volume":"286","author":"D Gouas","year":"2009","unstructured":"Gouas, D., Shi, H. & Hainaut, P. The aflatoxin-induced TP53 mutation at codon 249 (R249S): biomarker of exposure, early detection and target for therapy. Cancer Lett. 286, 29\u201337 (2009).","journal-title":"Cancer Lett."},{"key":"186_CR34","doi-asserted-by":"publisher","first-page":"18213","DOI":"10.18632\/oncotarget.15313","volume":"8","author":"MW Weng","year":"2017","unstructured":"Weng, M. W. et al. AFB1 hepatocarcinogenesis is via lipid peroxidation that inhibits DNA repair, sensitizes mutation susceptibility and induces aldehyde-DNA adducts at p53 mutational hotspot codon 249. Oncotarget 8, 18213\u201318226 (2017).","journal-title":"Oncotarget"},{"key":"186_CR35","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nrg3729","volume":"15","author":"T Helleday","year":"2014","unstructured":"Helleday, T., Eshtad, S. & Nik-Zainal, S. Mechanisms underlying mutational signatures in human cancers. Nat. Rev. Genet. 15, 585\u2013598 (2014).","journal-title":"Nat. Rev. Genet."},{"key":"186_CR36","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0165-1110(96)90005-6","volume":"366","author":"HM Shen","year":"1996","unstructured":"Shen, H. M. & Ong, C. N. Mutations of the p53 tumor suppressor gene and ras oncogenes in aflatoxin hepatocarcinogenesis. Mutat. Res. 366, 23\u201344 (1996).","journal-title":"Mutat. Res."},{"key":"186_CR37","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/0140-6736(92)91528-G","volume":"339","author":"RK Ross","year":"1992","unstructured":"Ross, R. K. et al. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 339, 943\u2013946 (1992).","journal-title":"Lancet"},{"key":"186_CR38","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1478-3231.2003.00869.x","volume":"23","author":"MC Kew","year":"2003","unstructured":"Kew, M. C. Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis. Liver Int. 23, 405\u2013409 (2003).","journal-title":"Liver Int."},{"key":"186_CR39","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1093\/mutage\/17.4.265","volume":"17","author":"VM Arlt","year":"2002","unstructured":"Arlt, V. M., Stiborova, M. & Schmeiser, H. H. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis 17, 265\u2013277 (2002).","journal-title":"Mutagenesis"},{"key":"186_CR40","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.dnarep.2016.05.027","volume":"44","author":"TA Rosenquist","year":"2016","unstructured":"Rosenquist, T. A. & Grollman, A. P. Mutational signature of aristolochic acid: clue to the recognition of a global disease. DNA Repair (Amst.) 44, 205\u2013211 (2016).","journal-title":"DNA Repair (Amst.)"},{"key":"186_CR41","doi-asserted-by":"publisher","first-page":"eaan6446","DOI":"10.1126\/scitranslmed.aan6446","volume":"9","author":"AWT Ng","year":"2017","unstructured":"Ng, A. W. T. et al. Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia. Sci. Transl Med. 9, eaan6446 (2017).","journal-title":"Sci. Transl Med."},{"key":"186_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/1749-8546-3-13","volume":"3","author":"SC Hsieh","year":"2008","unstructured":"Hsieh, S. C., Lin, I. H., Tseng, W. L., Lee, C. H. & Wang, J. D. Prescription profile of potentially aristolochic acid containing Chinese herbal products: an analysis of National Health Insurance data in Taiwan between 1997 and 2003. Chin. Med. 3, 13 (2008).","journal-title":"Chin. Med."},{"issue":"7","key":"186_CR43","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1002\/ijc.31544","volume":"143","author":"Chi-Jen Chen","year":"2018","unstructured":"Chen, C. J. et al. Herbal medicine containing aristolochic acid and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. In. J. Cancer, 143, 1578\u20131587 (2018).","journal-title":"International Journal of Cancer"},{"key":"186_CR44","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/CEJ.0000000000000252","volume":"26","author":"F Bravi","year":"2017","unstructured":"Bravi, F., Tavani, A., Bosetti, C., Boffetta, P. & La Vecchia, C. Coffee and the risk of hepatocellular carcinoma and chronic liver disease: a systematic review and meta-analysis of prospective studies. Eur.\u00a0J. Cancer Prev. 26, 368\u2013377 (2017).","journal-title":"Eur. J. Cancer Prev."},{"key":"186_CR45","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1053\/j.gastro.2012.10.005","volume":"144","author":"S Singh","year":"2013","unstructured":"Singh, S., Singh, P. P., Singh, A. G., Murad, M. H. & Sanchez, W. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 144, 323\u2013332 (2013).","journal-title":"Gastroenterology"},{"key":"186_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/srep33743","volume":"6","author":"YY Zhou","year":"2016","unstructured":"Zhou, Y. Y. et al. Systematic review with network meta-analysis: antidiabetic medication and risk of hepatocellular carcinoma. Sci. Rep. 6, 33743 (2016).","journal-title":"Sci. Rep."},{"key":"186_CR47","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1093\/jnci\/djs452","volume":"104","author":"VV Sahasrabuddhe","year":"2012","unstructured":"Sahasrabuddhe, V. V. et al. Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. J. Natl Cancer Inst. 104, 1808\u20131814 (2012).","journal-title":"J. Natl Cancer Inst."},{"key":"186_CR48","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"European Association for the Study of the Liver.","year":"2018","unstructured":"European Association for the Study of the Liver. EASL\u00a0clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 69, 182\u2013236 (2018).","journal-title":"J. Hepatol."},{"key":"186_CR49","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1002\/cncr.29537","volume":"121","author":"WR Kim","year":"2015","unstructured":"Kim, W. R. et al. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. Cancer 121, 3631\u20133638 (2015).","journal-title":"Cancer"},{"key":"186_CR50","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1001\/jama.2012.144878","volume":"308","author":"AJ van der Meer","year":"2012","unstructured":"van der Meer, A. J. et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308, 2584\u20132593 (2012).","journal-title":"JAMA"},{"key":"186_CR51","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/hep.28535","volume":"64","author":"HB El-Serag","year":"2016","unstructured":"El-Serag, H. B., Kanwal, F., Richardson, P. & Kramer, J. Risk of hepatocellular carcinoma after sustained virological response in veterans with hepatitis C virus infection. Hepatology 64, 130\u2013137 (2016).","journal-title":"Hepatology"},{"key":"186_CR52","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","volume":"153","author":"F Kanwal","year":"2017","unstructured":"Kanwal, F. et al. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology 153, 996\u20131005 e1001 (2017).","journal-title":"Gastroenterology"},{"key":"186_CR53","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","volume":"65","author":"M Reig","year":"2016","unstructured":"Reig, M. et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J. Hepatol. 65, 719\u2013726 (2016).","journal-title":"J. Hepatol."},{"key":"186_CR54","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","volume":"65","author":"F Conti","year":"2016","unstructured":"Conti, F. et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J. Hepatol. 65, 727\u2013733 (2016).","journal-title":"J. Hepatol."},{"key":"186_CR55","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.jhep.2016.06.023","volume":"65","author":"JD Yang","year":"2016","unstructured":"Yang, J. D. et al. Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma. J.\u00a0Hepatol. 65, 859\u2013860 (2016).","journal-title":"J. Hepatol."},{"key":"186_CR56","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1053\/j.gastro.2016.12.021","volume":"152","author":"S Ravi","year":"2017","unstructured":"Ravi, S. et al. Unusually high rates of hepatocellular carcinoma after treatment with direct-acting antiviral therapy for hepatitis c related cirrhosis. Gastroenterology 152, 911\u2013912 (2017).","journal-title":"Gastroenterology"},{"key":"186_CR57","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.jhep.2016.05.045","volume":"65","author":"ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER\u200a, CO12 CirVir and CO23CUPILT cohorts).","year":"2016","unstructured":"ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J. Hepatol. 65, 734\u2013740 (2016).","journal-title":"J. Hepatol."},{"key":"186_CR58","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/apt.13821","volume":"45","author":"S Petta","year":"2017","unstructured":"Petta, S. et al. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon. Aliment. Pharmacol. Ther. 45, 160\u2013168 (2017).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"186_CR59","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1053\/j.gastro.2019.01.027","volume":"156","author":"AG Singal","year":"2019","unstructured":"Singal, A. G. et al. Direct-acting antiviral therapy not associated with recurrence of hepatocellular carcinoma in a multicenter North American cohort study. Gastroenterology 156, 1683\u20131692 (2019).","journal-title":"Gastroenterology"},{"key":"186_CR60","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1053\/j.gastro.2018.07.015","volume":"155","author":"P Nahon","year":"2018","unstructured":"Nahon, P. et al. Incidence of hepatocellular carcinoma after direct antiviral therapy for HCV in patients with cirrhosis included in surveillance programs. Gastroenterology 155, 1436\u20131450 e1436 (2018).","journal-title":"Gastroenterology"},{"key":"186_CR61","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.cell.2017.05.046","volume":"169","author":"The Cancer Genome Atlas Research Network.","year":"2017","unstructured":"The Cancer Genome Atlas Research Network. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell 169, 1327\u20131341 e1323 (2017).","journal-title":"Cell"},{"key":"186_CR62","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/ng.3252","volume":"47","author":"K Schulze","year":"2015","unstructured":"Schulze, K. et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat. Genet. 47, 505\u2013511 (2015).","journal-title":"Nat. Genet."},{"key":"186_CR63","doi-asserted-by":"publisher","first-page":"7385","DOI":"10.1158\/0008-5472.CAN-09-1089","volume":"69","author":"Y Hoshida","year":"2009","unstructured":"Hoshida, Y. et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 69, 7385\u20137392 (2009).","journal-title":"Cancer Res."},{"key":"186_CR64","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1136\/gutjnl-2013-306228","volume":"64","author":"G Amaddeo","year":"2015","unstructured":"Amaddeo, G. et al. Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas. Gut 64, 820\u2013829 (2015).","journal-title":"Gut"},{"key":"186_CR65","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/hep.21467","volume":"45","author":"S Boyault","year":"2007","unstructured":"Boyault, S. et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45, 42\u201352 (2007).","journal-title":"Hepatology"},{"key":"186_CR66","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jhep.2017.05.014","volume":"67","author":"J Calderaro","year":"2017","unstructured":"Calderaro, J. et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J.\u00a0Hepatol. 67, 727\u2013738 (2017).","journal-title":"J. Hepatol."},{"key":"186_CR67","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1158\/1078-0432.CCR-18-2293","volume":"25","author":"JJ Harding","year":"2019","unstructured":"Harding, J. J. et al. Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. Clin. Cancer Res. 25, 2116\u20132126 (2019).","journal-title":"Clin. Cancer Res."},{"key":"186_CR68","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1053\/j.gastro.2016.05.048","volume":"151","author":"MH Chang","year":"2016","unstructured":"Chang, M. H. et al. Long-term effects of hepatitis B immunization of infants in preventing liver cancer. Gastroenterology 151, 472\u2013480 (2016).","journal-title":"Gastroenterology"},{"key":"186_CR69","unstructured":"World Health Organization. WHO\u2013UNICEF estimates of HepB3 coverage. WHO. http:\/\/apps.who.int\/immunization_monitoring\/globalsummary\/timeseries\/tswucoveragehepb3.html (2019)."},{"key":"186_CR70","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa1708131","volume":"378","author":"G Jourdain","year":"2018","unstructured":"Jourdain, G. et al. Tenofovir versus placebo to prevent perinatal transmission of hepatitis B. N. Engl. J. Med. 378, 911\u2013923 (2018).","journal-title":"N. Engl. J. Med."},{"key":"186_CR71","first-page":"CD008545","volume":"2","author":"AC Eke","year":"2017","unstructured":"Eke, A. C., Eleje, G. U., Eke, U. A., Xia, Y. & Liu, J. Hepatitis B immunoglobulin during pregnancy for prevention of mother-to-child transmission of hepatitis B virus. Cochrane Database Syst. Rev. 2, CD008545 (2017).","journal-title":"Cochrane Database Syst. Rev."},{"key":"186_CR72","doi-asserted-by":"publisher","first-page":"817","DOI":"10.7326\/0003-4819-157-9-201211060-00529","volume":"157","author":"BD Smith","year":"2012","unstructured":"Smith, B. D. et al. Hepatitis C virus testing of persons born during 1945\u20131965: recommendations from the centers for disease control and prevention. Ann.\u00a0Intern. Med. 157, 817\u2013822 (2012).","journal-title":"Ann. Intern. Med."},{"key":"186_CR73","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.jhep.2010.02.035","volume":"53","author":"GV Papatheodoridis","year":"2010","unstructured":"Papatheodoridis, G. V., Lampertico, P., Manolakopoulos, S. & Lok, A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J. Hepatol. 53, 348\u2013356 (2010).","journal-title":"J. Hepatol."},{"key":"186_CR74","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1056\/NEJMra1810477","volume":"380","author":"DL Thoms","year":"2019","unstructured":"Thoms, D. L. Global elimination of chronic hepatitis. N. Engl. J. Med. 380, 2041\u20132050 (2019).","journal-title":"N. Engl. J. Med."},{"key":"186_CR75","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.cgh.2016.09.150","volume":"15","author":"NS Patel","year":"2017","unstructured":"Patel, N. S. et al. Weight loss decreases magnetic resonance elastography estimated liver stiffness in nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 15, 463\u2013464 (2017).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"186_CR76","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/s41416-018-0007-z","volume":"118","author":"JL Petrick","year":"2018","unstructured":"Petrick, J. L. et al. Tobacco, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: the liver cancer pooling project. Br. J. Cancer 118, 1005\u20131012 (2018).","journal-title":"Br. J. Cancer"},{"key":"186_CR77","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/j.ejca.2012.02.009","volume":"48","author":"Y Liu","year":"2012","unstructured":"Liu, Y., Chang, C. C., Marsh, G. M. & Wu, F. Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis. Eur. J. Cancer 48, 2125\u20132136 (2012).","journal-title":"Eur. J. Cancer"},{"key":"186_CR78","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1016\/S0140-6736(05)66661-5","volume":"365","author":"PC Turner","year":"2005","unstructured":"Turner, P. C. et al. Reduction in exposure to carcinogenic aflatoxins by postharvest intervention measures in West Africa: a community-based intervention study. Lancet 365, 1950\u20131956 (2005).","journal-title":"Lancet"},{"key":"186_CR79","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1158\/1940-6207.CAPR-13-0168","volume":"6","author":"JG Chen","year":"2013","unstructured":"Chen, J. G. et al. Reduced aflatoxin exposure presages decline in liver cancer mortality in an endemic region of China. Cancer Prev. Res. 6, 1038\u20131045 (2013).","journal-title":"Cancer Prev. Res. (Phila.)"},{"key":"186_CR80","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero, J. A. et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatology 68, 723\u2013750 (2018).","journal-title":"Hepatology"},{"key":"186_CR81","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jhep.2015.11.035","volume":"64","author":"G Papatheodoridis","year":"2016","unstructured":"Papatheodoridis, G. et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in caucasians with chronic hepatitis B on 5-year antiviral therapy. J.\u00a0Hepatol. 64, 800\u2013806 (2016).","journal-title":"J. Hepatol."},{"key":"186_CR82","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001624","volume":"11","author":"AG Singal","year":"2014","unstructured":"Singal, A. G., Pillai, A. & Tiro, J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a\u00a0meta-analysis. PLOS Med. 11, e1001624 (2014).","journal-title":"PLOS Med."},{"key":"186_CR83","unstructured":"National Cancer Institute (ed.) PDQ Cancer Information Summaries, 2019. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK65785\/ (NCBI, 2019)."},{"key":"186_CR84","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1002\/hep.24581","volume":"54","author":"H Poustchi","year":"2011","unstructured":"Poustchi, H. et al. Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed? Hepatology 54, 1998\u20132004 (2011).","journal-title":"Hepatology"},{"key":"186_CR85","doi-asserted-by":"publisher","first-page":"519783","DOI":"10.4061\/2011\/519783","volume":"2011","author":"CH Tan","year":"2011","unstructured":"Tan, C. H., Low, S. C. & Thng, C. H. APASL and AASLD consensus guidelines on imaging diagnosis of hepatocellular carcinoma: a review. Int. J. Hepatol. 2011, 519783 (2011).","journal-title":"Int. J. Hepatol."},{"key":"186_CR86","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.jhep.2010.03.010","volume":"53","author":"V Santi","year":"2010","unstructured":"Santi, V. et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J.\u00a0Hepatol. 53, 291\u2013297 (2010).","journal-title":"J. Hepatol."},{"key":"186_CR87","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1002\/hep.24545","volume":"54","author":"JC Trinchet","year":"2011","unstructured":"Trinchet, J. C. et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology 54, 1987\u20131997 (2011).","journal-title":"Hepatology"},{"key":"186_CR88","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/ajg.2015.100","volume":"110","author":"TS Chang","year":"2015","unstructured":"Chang, T. S. et al. Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis. Am. J. Gastroenterol. 110, 836\u2013845 (2015).","journal-title":"Am. J. Gastroenterol."},{"key":"186_CR89","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1053\/jhep.2000.17914","volume":"32","author":"BJ McMahon","year":"2000","unstructured":"McMahon, B. J. et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 32, 842\u2013846 (2000).","journal-title":"Hepatology"},{"key":"186_CR90","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1158\/1055-9965.EPI-16-0747","volume":"26","author":"JD Yang","year":"2017","unstructured":"Yang, J. D. et al. Improved performance of serum alpha-fetoprotein for hepatocellular carcinoma diagnosis in HCV cirrhosis with normal alanine transaminase. Cancer Epidemiol. Biomarkers Prev. 26, 1085\u20131092 (2017).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"186_CR91","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1053\/j.gastro.2014.01.045","volume":"146","author":"HB El-Serag","year":"2014","unstructured":"El-Serag, H. B., Kanwal, F., Davila, J. A., Kramer, J. &\u00a0Richardson, P. A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis. Gastroenterology 146, 1249\u20131255 (2014).","journal-title":"Gastroenterology"},{"key":"186_CR92","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.cgh.2015.07.049","volume":"14","author":"N Tayob","year":"2016","unstructured":"Tayob, N., Lok, A. S., Do, K. A. & Feng, Z. Improved detection of hepatocellular carcinoma by using a longitudinal alpha-fetoprotein screening algorithm. Clin. Gastroenterol. Hepatol. 14, 469\u2013475 (2016).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"186_CR93","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1053\/j.gastro.2009.04.005","volume":"137","author":"JA Marrero","year":"2009","unstructured":"Marrero, J. A. et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 137, 110\u2013118 (2009).","journal-title":"Gastroenterology"},{"key":"186_CR94","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1053\/j.gastro.2009.10.031","volume":"138","author":"AS Lok","year":"2010","unstructured":"Lok, A. S. et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 138, 493\u2013502 (2010).","journal-title":"Gastroenterology"},{"key":"186_CR95","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.cgh.2015.12.042","volume":"14","author":"S Berhane","year":"2016","unstructured":"Berhane, S. et al. Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients. Clin.\u00a0Gastroenterol. Hepatol. 14, 875\u2013886 (2016).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"186_CR96","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1158\/1055-9965.EPI-13-0870","volume":"23","author":"PJ Johnson","year":"2014","unstructured":"Johnson, P. J. et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol. Biomarkers Prev. 23, 144\u2013153 (2014).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"186_CR97","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1158\/1055-9965.EPI-18-0281","volume":"28","author":"JD Yang","year":"2019","unstructured":"Yang, J. D. et al. GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score. Cancer Epidemiol. Biomarkers Prev. 28, 531\u2013538 (2019).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"186_CR98","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/S1470-2045(15)00048-0","volume":"16","author":"XJ Lin","year":"2015","unstructured":"Lin, X. J. et al. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. Lancet Oncol. 16, 804\u2013815 (2015).","journal-title":"Lancet Oncol."},{"key":"186_CR99","doi-asserted-by":"publisher","DOI":"10.1186\/1868-7083-6-30","volume":"6","author":"Y Zhao","year":"2014","unstructured":"Zhao, Y. et al. Genome-wide methylation profiling of the different stages of hepatitis B virus-related hepatocellular carcinoma development in plasma cell-free DNA reveals potential biomarkers for early detection and high-risk monitoring of hepatocellular carcinoma. Clin. Epigenet. 6, 30 (2014).","journal-title":"Clin. Epigenetics"},{"key":"186_CR100","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000722","volume":"94","author":"W Liao","year":"2015","unstructured":"Liao, W. et al. Value of quantitative and qualitative analyses of circulating cell-free DNA as diagnostic tools for hepatocellular carcinoma: a meta-analysis. Medicine 94, e722 (2015).","journal-title":"Medicine (Baltimore)"},{"key":"186_CR101","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/hep.24703","volume":"55","author":"S Shang","year":"2012","unstructured":"Shang, S. et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology 55, 483\u2013490 (2012).","journal-title":"Hepatology"},{"key":"186_CR102","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/hep.30244","volume":"69","author":"JB Kisiel","year":"2019","unstructured":"Kisiel, J. B. et al. Hepatocellular carcinoma detection by plasma methylated DNA: discovery, phase I pilot, and phase II clinical validation. Hepatology 69, 1180\u20131192 (2019).","journal-title":"Hepatology"},{"key":"186_CR103","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1002\/hep.28895","volume":"65","author":"O Atiq","year":"2017","unstructured":"Atiq, O. et al. An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. Hepatology 65, 1196\u20131205 (2017).","journal-title":"Hepatology"},{"key":"186_CR104","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1055\/s-0037-1608775","volume":"37","author":"NE Rich","year":"2017","unstructured":"Rich, N. E., Parikh, N. D. & Singal, A. G. Overdiagnosis: an understudied issue in hepatocellular carcinoma surveillance. Semin. Liver Dis. 37, 296\u2013304 (2017).","journal-title":"Semin. Liver Dis."},{"key":"186_CR105","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1002\/hep.27304","volume":"61","author":"DG Mitchell","year":"2015","unstructured":"Mitchell, D. G., Bruix, J., Sherman, M. & Sirlin, C. B. LI-RADS (liver imaging reporting and data system): summary, discussion, and consensus of the LI-RADS management working group and future directions. Hepatology 61, 1056\u20131065 (2015).","journal-title":"Hepatology"},{"key":"186_CR106","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1148\/radiol.2017170554","volume":"286","author":"A Tang","year":"2018","unstructured":"Tang, A. et al. Evidence supporting LI-RADS major features for CT- and MR imaging-based diagnosis of hepatocellular carcinoma: a systematic review. Radiology 286, 29\u201348 (2018).","journal-title":"Radiology"},{"key":"186_CR107","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.jhep.2015.10.029","volume":"64","author":"PH Liu","year":"2016","unstructured":"Liu, P. H. et al. Prognosis of hepatocellular carcinoma: assessment of eleven staging systems. J. Hepatol. 64, 601\u2013608 (2016).","journal-title":"J. Hepatol."},{"key":"186_CR108","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1055\/s-2007-1007122","volume":"19","author":"JM Llovet","year":"1999","unstructured":"Llovet, J. M., Bru, C. & Bruix, J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis. 19, 329\u2013338 (1999).","journal-title":"Semin. Liver Dis."},{"key":"186_CR109","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","volume":"391","author":"A Forner","year":"2018","unstructured":"Forner, A., Reig, M. & Bruix, J. Hepatocellular carcinoma. Lancet 391, 1301\u20131314 (2018).","journal-title":"Lancet"},{"key":"186_CR110","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/ajg.2015.389","volume":"111","author":"EG Giannini","year":"2016","unstructured":"Giannini, E. G. et al. Application of the intermediate-stage subclassification to patients with untreated hepatocellular carcinoma. Am. J. Gastroenterol. 111, 70\u201377 (2016).","journal-title":"Am. J. Gastroenterol."},{"key":"186_CR111","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1002\/hep.20486","volume":"40","author":"M Kudo","year":"2004","unstructured":"Kudo, M. et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 40, 1396\u20131405 (2004).","journal-title":"Hepatology"},{"key":"186_CR112","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000447061","volume":"91","author":"A Hiraoka","year":"2016","unstructured":"Hiraoka, A. et al. Proposed new sub-grouping for intermediate-stage hepatocellular carcinoma using albumin-bilirubin grade. Oncology 91, 153\u2013161 (2016).","journal-title":"Oncology"},{"key":"186_CR113","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","volume":"33","author":"PJ Johnson","year":"2015","unstructured":"Johnson, P. J. et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach\u2014the ALBI grade. J. Clin. Oncol. 33, 550\u2013558 (2015).","journal-title":"J. Clin. Oncol."},{"key":"186_CR114","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1053\/j.gastro.2014.02.032","volume":"146","author":"T Yau","year":"2014","unstructured":"Yau, T. et al. Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 146, 1691\u20131700 (2014).","journal-title":"Gastroenterology"},{"key":"186_CR115","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.cgh.2016.10.036","volume":"15","author":"JH Sohn","year":"2017","unstructured":"Sohn, J. H. et al. Validation of the Hong Kong liver cancer staging system in determining prognosis of the North American patients following intra-arterial therapy. Clin. Gastroenterol. Hepatol. 15, 746\u2013755 (2017).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"186_CR116","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jhep.2015.12.008","volume":"64","author":"L Wu","year":"2016","unstructured":"Wu, L., Bartlett, A., Plank, L. & McCall, J. Validation of the Hong Kong liver cancer staging system in hepatocellular carcinoma patients treated with curative intent. J. Hepatol. 64, 978\u2013979 (2016).","journal-title":"J. Hepatol."},{"key":"186_CR117","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/hep.25680","volume":"56","author":"JD Yang","year":"2012","unstructured":"Yang, J. D. et al. Model to estimate survival in ambulatory patients with hepatocellular carcinoma. Hepatology 56, 614\u2013621 (2012).","journal-title":"Hepatology"},{"key":"186_CR118","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002006","volume":"13","author":"F Farinati","year":"2016","unstructured":"Farinati, F. et al. Development and validation of a new prognostic system for patients with hepatocellular carcinoma. PLOS Med. 13, e1002006 (2016).","journal-title":"PLOS Med."},{"key":"186_CR119","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/j.cgh.2006.09.021","volume":"4","author":"H Toyoda","year":"2006","unstructured":"Toyoda, H. et al. Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Clin. Gastroenterol. Hepatol. 4, 1528\u20131536 (2006).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"186_CR120","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1053\/j.gastro.2017.02.040","volume":"152","author":"M Serper","year":"2017","unstructured":"Serper, M. et al. Association of provider specialty and multidisciplinary care with hepatocellular carcinoma treatment and mortality. Gastroenterology 152, 1954\u20131964 (2017).","journal-title":"Gastroenterology"},{"key":"186_CR121","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1002\/hep.27431","volume":"61","author":"A Berzigotti","year":"2015","unstructured":"Berzigotti, A., Reig, M., Abraldes, J. G., Bosch, J. &\u00a0Bruix, J. Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology 61, 526\u2013536 (2015).","journal-title":"Hepatology"},{"key":"186_CR122","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/bjs.8753","volume":"99","author":"E Boleslawski","year":"2012","unstructured":"Boleslawski, E. et al. Hepatic venous pressure gradient in the assessment of portal hypertension before liver resection in patients with cirrhosis. Br. J. Surg. 99, 855\u2013863 (2012).","journal-title":"Br. J. Surg."},{"key":"186_CR123","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.gassur.2005.09.008","volume":"9","author":"SH Teh","year":"2005","unstructured":"Teh, S. H. et al. Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality. J. Gastrointest. Surg. 9, 1207\u20131215 (2005).","journal-title":"J. Gastrointest. Surg."},{"key":"186_CR124","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/hep.27745","volume":"62","author":"S Roayaie","year":"2015","unstructured":"Roayaie, S. et al. The role of hepatic resection in the treatment of hepatocellular cancer. Hepatology 62, 440\u2013451 (2015).","journal-title":"Hepatology"},{"key":"186_CR125","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1002\/bjs.10541","volume":"104","author":"H Kim","year":"2017","unstructured":"Kim, H. et al. Survival benefit of liver resection for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma. Br. J. Surg. 104, 1045\u20131052 (2017).","journal-title":"Br. J. Surg."},{"key":"186_CR126","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1097\/SLA.0000000000000710","volume":"261","author":"P Tabrizian","year":"2015","unstructured":"Tabrizian, P., Jibara, G., Shrager, B., Schwartz, M. & Roayaie, S. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann. Surg. 261, 947\u2013955 (2015).","journal-title":"Ann. Surg."},{"key":"186_CR127","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa0804525","volume":"359","author":"Y Hoshida","year":"2008","unstructured":"Hoshida, Y. et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N. Engl. J. Med. 359, 1995\u20132004 (2008).","journal-title":"N. Engl. J. Med."},{"key":"186_CR128","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1002\/hep.28339","volume":"63","author":"J Ferrer-Fabrega","year":"2016","unstructured":"Ferrer-Fabrega, J. et al. Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection. Hepatology 63, 839\u2013849 (2016).","journal-title":"Hepatology"},{"key":"186_CR129","doi-asserted-by":"publisher","first-page":"26","DOI":"10.21037\/apm.2016.11.02","volume":"6","author":"AY Hammad","year":"2017","unstructured":"Hammad, A. Y. et al. Palliative interventions for hepatocellular carcinoma patients: analysis of the National Cancer Database. Ann. Palliat. Med. 6, 26\u201335 (2017).","journal-title":"Ann. Palliat. Med."},{"key":"186_CR130","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1002\/cncr.21811","volume":"106","author":"MA Hawkins","year":"2006","unstructured":"Hawkins, M. A. & Dawson, L. A. Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer 106, 1653\u20131663 (2006).","journal-title":"Cancer"},{"key":"186_CR131","doi-asserted-by":"publisher","first-page":"923","DOI":"10.4254\/wjh.v6.i12.923","volume":"6","author":"S Hayashi","year":"2014","unstructured":"Hayashi, S., Tanaka, H. & Hoshi, H. Palliative external-beam radiotherapy for bone metastases from hepatocellular carcinoma. World J. Hepatol. 6, 923\u2013929 (2014).","journal-title":"World J. Hepatol."},{"key":"186_CR132","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.cgh.2016.11.034","volume":"15","author":"JD Yang","year":"2017","unstructured":"Yang, J. D. et al. Hepatocellular carcinoma is the most common indication for liver transplantation and placement on the waitlist in the United States. Clin.\u00a0Gastroenterol. Hepatol. 15, 767\u2013775 (2017).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"186_CR133","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJM199603143341104","volume":"334","author":"V Mazzaferro","year":"1996","unstructured":"Mazzaferro, V. et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 334, 693\u2013699 (1996).","journal-title":"N. Engl. J. Med."},{"key":"186_CR134","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/lt.20526","volume":"11","author":"FY Yao","year":"2005","unstructured":"Yao, F. Y. et al. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl. 11, 1505\u20131514 (2005).","journal-title":"Liver Transpl."},{"key":"186_CR135","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","volume":"10","author":"V Mazzaferro","year":"2009","unstructured":"Mazzaferro, V. et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 10, 35\u201343 (2009).","journal-title":"Lancet Oncol."},{"key":"186_CR136","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1053\/jhep.2001.24563","volume":"33","author":"FY Yao","year":"2001","unstructured":"Yao, F. Y. et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33, 1394\u20131403 (2001).","journal-title":"Hepatology"},{"key":"186_CR137","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1053\/jlts.2002.34892","volume":"8","author":"FY Yao","year":"2002","unstructured":"Yao, F. Y. et al. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl. 8, 765\u2013774 (2002).","journal-title":"Liver Transpl."},{"key":"186_CR138","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1111\/j.1600-6143.2007.01965.x","volume":"7","author":"FY Yao","year":"2007","unstructured":"Yao, F. Y. et al. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am. J. Transplant. 7, 2587\u20132596 (2007).","journal-title":"Am. J. Transplant."},{"key":"186_CR139","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1002\/hep.22412","volume":"48","author":"FY Yao","year":"2008","unstructured":"Yao, F. Y. et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 48, 819\u2013827 (2008).","journal-title":"Hepatology"},{"key":"186_CR140","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.cgh.2017.11.037","volume":"16","author":"N Mehta","year":"2018","unstructured":"Mehta, N. et al. Excellent outcomes of liver transplantation following down-staging of hepatocellular carcinoma to within Milan criteria: a\u00a0multicenter study. Clin. Gastroenterol. Hepatol. 16, 955\u2013964 (2018).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"186_CR141","doi-asserted-by":"publisher","first-page":"4756147","DOI":"10.1155\/2018\/4756147","volume":"2018","author":"S Shiina","year":"2018","unstructured":"Shiina, S. et al. Percutaneous ablation for hepatocellular carcinoma: comparison of various ablation techniques and surgery. Can. J. Gastroenterol. Hepatol. 2018, 4756147 (2018).","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"186_CR142","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1136\/gutjnl-2016-312629","volume":"66","author":"J Yu","year":"2017","unstructured":"Yu, J. et al. Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: a phase III randomised controlled trial. Gut 66, 1172\u20131173 (2017).","journal-title":"Gut"},{"key":"186_CR143","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/apt.14929","volume":"48","author":"W Liu","year":"2018","unstructured":"Liu, W. et al. Microwave vs radiofrequency ablation for hepatocellular carcinoma within the Milan criteria: a\u00a0propensity score analysis. Aliment. Pharmacol. Ther. 48, 671\u2013681 (2018).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"186_CR144","doi-asserted-by":"publisher","first-page":"5331","DOI":"10.3748\/wjg.v24.i47.5331","volume":"24","author":"TW Kang","year":"2018","unstructured":"Kang, T. W., Lim, H. K. & Cha, D. I. Percutaneous ablation for perivascular hepatocellular carcinoma: refining the current status based on emerging evidence and future perspectives. World. J. Gastroenterol. 24, 5331\u20135337 (2018).","journal-title":"World. J. Gastroenterol."},{"key":"186_CR145","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S2468-1253(18)30029-3","volume":"3","author":"N Vietti Violi","year":"2018","unstructured":"Vietti Violi, N. et al. Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial. Lancet Gastroenterol. Hepatol. 3, 317\u2013325 (2018).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"186_CR146","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s00270-016-1384-4","volume":"39","author":"GM Kim","year":"2016","unstructured":"Kim, G. M. et al. Cryoablation of hepatocellular carcinoma with high-risk for percutaneous ablation: safety and efficacy. Cardiovasc. Intervent. Radiol. 39, 1447\u20131454 (2016).","journal-title":"Cardiovasc. Intervent. Radiol."},{"key":"186_CR147","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00261-016-0687-x","volume":"41","author":"PJ Littrup","year":"2016","unstructured":"Littrup, P. J. et al. Percutaneous cryoablation of hepatic tumors: long-term experience of a large U.S. series. Abdom. Radiol. 41, 767\u2013780 (2016).","journal-title":"Abdom. Radiol. (NY)"},{"key":"186_CR148","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1007\/s00330-017-4740-0","volume":"27","author":"Y Xu","year":"2017","unstructured":"Xu, Y. et al. Microwave ablation for the treatment of hepatocellular carcinoma that met up-to-seven criteria: feasibility, local efficacy and long-term outcomes. Eur. Radiol. 27, 3877\u20133887 (2017).","journal-title":"Eur. Radiol."},{"key":"186_CR149","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1002\/hep.29098","volume":"65","author":"MW Lee","year":"2017","unstructured":"Lee, M. W. et al. Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: a 10-year intention-to-treat analysis. Hepatology 65, 1979\u20131990 (2017).","journal-title":"Hepatology"},{"key":"186_CR150","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hep.29086","volume":"67","author":"JK Heimbach","year":"2018","unstructured":"Heimbach, J. K. et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67, 358\u2013380 (2018).","journal-title":"Hepatology"},{"key":"186_CR151","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1097\/SLA.0b013e3181efc656","volume":"252","author":"J Huang","year":"2010","unstructured":"Huang, J. et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann. Surg. 252, 903\u2013912 (2010).","journal-title":"Ann. Surg."},{"key":"186_CR152","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.jhep.2012.05.007","volume":"57","author":"K Feng","year":"2012","unstructured":"Feng, K. et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J.\u00a0Hepatol. 57, 794\u2013802 (2012).","journal-title":"J. Hepatol."},{"key":"186_CR153","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/01.sla.0000201480.65519.b8","volume":"243","author":"MS Chen","year":"2006","unstructured":"Chen, M. S. et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann. Surg. 243, 321\u2013328 (2006).","journal-title":"Ann. Surg."},{"key":"186_CR154","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/hep.28453","volume":"64","author":"R Lencioni","year":"2016","unstructured":"Lencioni, R., de Baere, T., Soulen, M. C., Rilling, W. S. & Geschwind, J. F. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology 64, 106\u2013116 (2016).","journal-title":"Hepatology"},{"key":"186_CR155","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","volume":"35","author":"CM Lo","year":"2002","unstructured":"Lo, C. M. et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35, 1164\u20131171 (2002).","journal-title":"Hepatology"},{"key":"186_CR156","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","volume":"359","author":"JM Llovet","year":"2002","unstructured":"Llovet, J. M. et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359, 1734\u20131739 (2002).","journal-title":"Lancet"},{"key":"186_CR157","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1200\/JCO.2015.64.0821","volume":"34","author":"KT Brown","year":"2016","unstructured":"Brown, K. T. et al. Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. J. Clin. Oncol. 34, 2046\u20132053 (2016).","journal-title":"J. Clin. Oncol."},{"key":"186_CR158","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s00270-012-0394-0","volume":"35","author":"K Malagari","year":"2012","unstructured":"Malagari, K. et al. Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc. Intervent. Radiol. 35, 1119\u20131128 (2012).","journal-title":"Cardiovasc. Intervent. Radiol."},{"key":"186_CR159","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/hep.21980","volume":"47","author":"LM Kulik","year":"2008","unstructured":"Kulik, L. M. et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 47, 71\u201381 (2008).","journal-title":"Hepatology"},{"key":"186_CR160","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1002\/hep.24451","volume":"54","author":"B Sangro","year":"2011","unstructured":"Sangro, B. et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 54, 868\u2013878 (2011).","journal-title":"Hepatology"},{"key":"186_CR161","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1053\/j.gastro.2010.10.049","volume":"140","author":"R Salem","year":"2011","unstructured":"Salem, R. et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 140, 497\u2013507 e492 (2011).","journal-title":"Gastroenterology"},{"key":"186_CR162","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1002\/hep.26014","volume":"57","author":"V Mazzaferro","year":"2013","unstructured":"Mazzaferro, V. et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 57, 1826\u20131837 (2013).","journal-title":"Hepatology"},{"key":"186_CR163","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1053\/j.gastro.2016.08.029","volume":"151","author":"R Salem","year":"2016","unstructured":"Salem, R. et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 151, 1155\u20131163 e1152 (2016).","journal-title":"Gastroenterology"},{"key":"186_CR164","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1007\/s00270-016-1426-y","volume":"39","author":"L Lobo","year":"2016","unstructured":"Lobo, L. et al. Unresectable hepatocellular carcinoma: radioembolization versus chemoembolization: a\u00a0systematic review and meta-analysis. Cardiovasc. Intervent. Radiol. 39, 1580\u20131588 (2016).","journal-title":"Cardiovasc. Intervent. Radiol."},{"key":"186_CR165","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1002\/cncr.24884","volume":"116","author":"BI Carr","year":"2010","unstructured":"Carr, B. I., Kondragunta, V., Buch, S. C. & Branch, R. A. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer 116, 1305\u20131314 (2010).","journal-title":"Cancer"},{"key":"186_CR166","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","volume":"36","author":"PKH Chow","year":"2018","unstructured":"Chow, P. K. H. et al. SIRveNIB: selective internal radiation therapy versus sorafenib in asia-pacific patients with hepatocellular carcinoma. J. Clin. Oncol. 36, 1913\u20131921 (2018).","journal-title":"J. Clin. Oncol."},{"key":"186_CR167","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","volume":"18","author":"V Vilgrain","year":"2017","unstructured":"Vilgrain, V. et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 18, 1624\u20131636 (2017).","journal-title":"Lancet Oncol."},{"key":"186_CR168","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.ijrobp.2016.02.027","volume":"95","author":"DA Bush","year":"2016","unstructured":"Bush, D. A. et al. Randomized clinical trial comparing proton beam radiation therapy with transarterial chemoembolization for hepatocellular carcinoma: results of an interim analysis. Int. J. Radiat. Oncol. Biol. Phys. 95, 477\u2013482 (2016).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"186_CR169","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/cas.13145","volume":"108","author":"K Fukuda","year":"2017","unstructured":"Fukuda, K. et al. Long-term outcomes of proton beam therapy in patients with previously untreated hepatocellular carcinoma. Cancer Sci. 108, 497\u2013503 (2017).","journal-title":"Cancer Sci."},{"key":"186_CR170","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1200\/JCO.2015.64.2710","volume":"34","author":"TS Hong","year":"2016","unstructured":"Hong, T. S. et al. Multi-institutional phase ii study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J.\u00a0Clin. Oncol. 34, 460\u2013468 (2016).","journal-title":"J. Clin. Oncol."},{"key":"186_CR171","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10147-017-1190-2","volume":"23","author":"H Igaki","year":"2018","unstructured":"Igaki, H. et al. A systematic review of publications on charged particle therapy for hepatocellular carcinoma. Int. J. Clin. Oncol. 23, 423\u2013433 (2018).","journal-title":"Int. J. Clin. Oncol."},{"key":"186_CR172","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ijrobp.2017.09.001","volume":"100","author":"E Sapir","year":"2018","unstructured":"Sapir, E. et al. Stereotactic body radiation therapy as an alternative to transarterial chemoembolization for hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 100, 122\u2013130 (2018).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"186_CR173","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jhep.2017.02.022","volume":"67","author":"G Sapisochin","year":"2017","unstructured":"Sapisochin, G. et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J. Hepatol. 67, 92\u201399 (2017).","journal-title":"J. Hepatol."},{"key":"186_CR174","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/hepr.12916","volume":"48","author":"Y Teraoka","year":"2018","unstructured":"Teraoka, Y. et al. Clinical outcomes of stereotactic body radiotherapy for elderly patients with hepatocellular carcinoma. Hepatol. Res. 48, 193\u2013204 (2018).","journal-title":"Hepatol. Res."},{"key":"186_CR175","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1159\/000475768","volume":"6","author":"ZC Zeng","year":"2017","unstructured":"Zeng, Z. C. et al. Consensus on stereotactic body radiation therapy for small-sized hepatocellular carcinoma at the 7th Asia-Pacific primary liver cancer expert meeting. Liver Cancer 6, 264\u2013274 (2017).","journal-title":"Liver Cancer"},{"key":"186_CR176","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378\u2013390 (2008).","journal-title":"N. Engl. J. Med."},{"key":"186_CR177","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng, A. L. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase iii randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25\u201334 (2009).","journal-title":"Lancet Oncol."},{"key":"186_CR178","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/S1470-2045(15)00198-9","volume":"16","author":"J Bruix","year":"2015","unstructured":"Bruix, J. et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 16, 1344\u20131354 (2015).","journal-title":"Lancet Oncol."},{"key":"186_CR179","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.jhep.2016.01.012","volume":"64","author":"R Lencioni","year":"2016","unstructured":"Lencioni, R. et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. J. Hepatol. 64, 1090\u20131098 (2016).","journal-title":"J. Hepatol."},{"key":"186_CR180","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo, M. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391, 1163\u20131173 (2018).","journal-title":"Lancet"},{"key":"186_CR181","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","volume":"389","author":"J Bruix","year":"2017","unstructured":"Bruix, J. et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389, 56\u201366 (2017).","journal-title":"Lancet"},{"key":"186_CR182","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1717002","volume":"379","author":"GK Abou-Alfa","year":"2018","unstructured":"Abou-Alfa, G. K. et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N. Engl. J. Med. 379, 54\u201363 (2018).","journal-title":"N. Engl. J. Med."},{"key":"186_CR183","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","volume":"20","author":"AX Zhu","year":"2019","unstructured":"Zhu, A. X. et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 20, 282\u2013296 (2019).","journal-title":"Lancet Oncol."},{"key":"186_CR184","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1200\/JCO.2009.23.7537","volume":"28","author":"JL Spratlin","year":"2010","unstructured":"Spratlin, J. L. et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J. Clin. Oncol. 28, 780\u2013787 (2010).","journal-title":"J. Clin. Oncol."},{"key":"186_CR185","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry, A. B. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet 389, 2492\u20132502 (2017).","journal-title":"Lancet"},{"key":"186_CR186","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02576509 (2019)."},{"key":"186_CR187","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","volume":"19","author":"AX Zhu","year":"2018","unstructured":"Zhu, A. X. et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 19, 940\u2013952 (2018).","journal-title":"Lancet Oncol."},{"key":"186_CR188","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0140-6736(08)60181-6","volume":"371","author":"P Hainaut","year":"2008","unstructured":"Hainaut, P. & Boyle, P. Curbing the liver cancer epidemic in Africa. Lancet 371, 367\u2013368 (2008).","journal-title":"Lancet"},{"key":"186_CR189","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/jgh.12293","volume":"28","author":"LY Goh","year":"2013","unstructured":"Goh, L. Y. & Goh, K. L. Obesity: an epidemiological perspective from Asia and its relationship to gastrointestinal and liver cancers. J. Gastroenterol. Hepatol. 28, Suppl 4, 54\u201358, (2013).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"186_CR190","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1200\/JCO.2015.64.7412","volume":"34","author":"JL Petrick","year":"2016","unstructured":"Petrick, J. L., Kelly, S. P., Altekruse, S. F., McGlynn, K. A. & Rosenberg, P. S. Future of hepatocellular carcinoma incidence in the United States forecast through 2030. J. Clin. Oncol. 34, 1787\u20131794 (2016).","journal-title":"J. Clin. Oncol."},{"key":"186_CR191","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.7863\/ultra.16.05077","volume":"36","author":"IE Kjesbu","year":"2017","unstructured":"Kjesbu, I. E. et al. Feasibility and diagnostic accuracy of point-of-care abdominal sonography by pocket-sized imaging devices, performed by medical residents. J.\u00a0Ultrasound Med. 36, 1195\u20131202 (2017).","journal-title":"J. Ultrasound Med."},{"key":"186_CR192","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/20477724.2015.1126035","volume":"109","author":"Y Waheed","year":"2015","unstructured":"Waheed, Y. Transition from millennium development goals to sustainable development goals and hepatitis. Pathog. Glob. Health 109, 353 (2015).","journal-title":"Pathog. Glob. Health"},{"key":"186_CR193","unstructured":"Kenya Outreach Mission. IHPBA http:\/\/www.ihpba.org\/includes\/moxiemanager\/data\/files\/IHPBA%20Outreach%20Kenya%202017%20Leaflet%20WEBSITE.pdf. (2017)."}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41575-019-0186-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-019-0186-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-019-0186-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T06:33:01Z","timestamp":1695105181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41575-019-0186-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,22]]},"references-count":193,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["186"],"URL":"https:\/\/doi.org\/10.1038\/s41575-019-0186-y","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,22]]},"assertion":[{"value":"4 July 2019","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}